Ruling opens door for Noven’s oestrogen patch generics
In a victory for pharmaceutical company Amneal, a Delaware court has invalidated claims of three patents covering Noven Pharmaceuticals’ Minivelle oestrogen product.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
4 September 2020 Amarin has announced it will seek an en banc rehearing of a decision at the US Court of Appeals for the Federal Circuit that failed to revive its patents on heart medicine Vascepa.
5 June 2020 The US Court of Appeals for the Federal Circuit has said it cannot award attorneys’ fees for proceedings before the US Patent Trial and Appeal Board.